NeoGenomics delivered an 11% year-over-year revenue increase in Q1, exceeding Wall Street’s expectations for the period. Management attributed this performance to broad-based growth across clinical testing, led by robust expansion in next-generation sequencing (NGS) and continued progress in shifting the portfolio toward higher-value diagnostics. CEO Anthony Zook noted, “Our clinical business continued its robust growth with revenue increasing 14% year-over-year,” highlighting the company’s focus on commercial execution and product mix improvements in the oncology diagnostics market.
Is now the time to buy NEO? Find out in our full research report (it’s free for active Edge members).
NeoGenomics (NEO) Q1 CY2026 Highlights:
- Revenue: $186.7 million vs analyst estimates of $184.5 million (11.1% year-on-year growth, 1.2% beat)
- Adjusted EPS: $0.01 vs analyst estimates of $0 (in line)
- Adjusted EBITDA: $9.00 million vs analyst estimates of $8.33 million (4.8% margin, 8% beat)
- The company slightly lifted its revenue guidance for the full year to $800 million at the midpoint from $797 million
- EBITDA guidance for the full year is $56 million at the midpoint, in line with analyst expectations
- Operating Margin: -9.8%, up from -16.6% in the same quarter last year
- Market Capitalization: $1.17 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From NeoGenomics’s Q1 Earnings Call
- David Westenberg (Piper Sandler) asked about the sustainability of high NGS growth and whether PanTracer Liquid can maintain revenue expansion. CEO Anthony Zook responded that early indicators are favorable and the addition of liquid biopsy should enable growth above the 20% mark for NGS.
- Tycho Peterson (Jefferies) questioned the conservatism of guidance, given past adjustments. CFO Abhishek Jain explained the approach prioritizes confidence and balance, noting opportunity in NGS and nonclinical businesses but maintaining prudence due to market uncertainties.
- Puneet Souda (Leerink) inquired about the ceiling for NGS as a portion of the business and its definition. President Warren Stone clarified that NGS could reach over 40% of the clinical mix, driven by both heme and solid tumor applications, excluding MRD.
- William Bonello (Craig-Hallum) asked for details on PanTracer Pro’s workflow and incremental value. Stone explained the platform automates medically necessary add-on testing based on diagnosis, streamlining the process and potentially increasing revenue per test.
- Michael Ryskin (Bank of America) sought clarification on the sales force expansion’s impact and Pathline’s contribution. Zook said the sales force is a core growth lever, particularly for community oncology, and that Pathline’s main benefit is accelerating Northeast market share rather than direct volume.
Catalysts in Upcoming Quarters
In the upcoming quarters, the StockStory team will be closely monitoring (1) the pace of adoption and reimbursement for RaDaR ST and PanTracer Liquid in new cancer indications, (2) the effectiveness of the expanded sales force in driving volume and market penetration, and (3) the progress of lab automation and digital initiatives in supporting gross margin improvement. Additional signs of success will include increased uptake from Epic Aura integrations and stabilization in the nonclinical business.
NeoGenomics currently trades at $9.03, in line with $9.02 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
